Abiopharma

🔍 Wei Binxian (Director)

Company: PALISADE BIO, INC. (PALI)

Report Date: 2026-06-10

Detailed Transactions and Holdings:

• Acquired 592,300 shares of Common Stock (Direct)
  Date: 2026-06-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 593,155.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 20,200 shares of Common Stock (Direct)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 613,355.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 20,200 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,400.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
• F2: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.
• F3: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.